AptarGroup (ATR): The Unsung Hero of Reliable Dividend Growth

AptarGroup, Inc. (NYSE:ATR) was recently included on our list of Dividend Champion vs Aristocrats: 12 Under the Radar Stocks to Buy.

AptarGroup, Inc. (NYSE:ATR) has a global presence, generating about half of its revenue in Europe and 33% in North America. The company has completed nearly two dozen acquisitions, investments, and partnerships since 2016, expanding its reach and broadening its portfolio. The stock has surged by nearly 5% since the start of 2025.

AptarGroup, Inc. (NYSE:ATR) reported mixed earnings in the first quarter of 2025. The company posted revenue of $887 million, which showed a 3% decline from the same period last year. Pharma’s proprietary drug delivery systems delivered a 2% increase in reported sales and a 4% rise in core sales for the quarter. The company experienced heightened demand for its dosing, dispensing, and protection technologies across various segments, including treatments for central nervous system disorders, emergency medications, weight and diabetes management, and applications in food, beverage, and personal care.

AptarGroup, Inc. (NYSE:ATR) also posted a strong cash position during the quarter. The company’s operating cash flow was $82.7 million, and its free cash flow amounted to $25.8 million. It also returned $110 million to shareholders through dividends, which makes it one of the best stocks on our dividend champions list. The company has raised its payouts for 31 years in a row. Currently, it pays a quarterly dividend of $0.45 per share and has a dividend yield of 1.11%, as of July 23.

While we acknowledge the potential of ATR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Dividend Stocks to Buy Under $20 and 11 Best Halal Dividend Stocks to Buy Now

Disclosure: None.